ALLMedicine™ Hemochromatosis Center

May 15th, 2022 - The iron overload condition Hereditary Heamochromatosis (HH) can cause liver cirrhosis and cancer, diabetes and arthritis. Male HFE p.C282Y homozygotes have greatest risk, yet only a minority develop these conditions. We aimed to determine whether...

May 10th, 2022 - This study will evaluate the long term performance and safety data for the Cadence™ Total Ankle System (CTAS) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumat...

Apr 29th, 2022 - The purpose of this case study is to review the clinical presentation and medical workup of a young adult male presenting with rhabdomyolysis in the setting of suspected contributing factors, including treatment with mirtazapine and history of COV...

Apr 27th, 2022 - Iron overload is a severe general complication of hereditary anemias. Treatment with iron chelators is hampered by important side-effects, high costs, and the lack of availability in many countries with a high prevalence of hereditary anemias. In ...

Apr 19th, 2022 - Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatit...

Jul 25th, 2019 - Hereditary hemochromatosis (HH) is one of the most common genetic disorders among persons of northern European descent. There have been recent advances in the diagnosis, management, and treatment of HH. The availability of molecular diagnostic tes...

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

Jul 15th, 2015 - Molecular genetic testing for hereditary hemochromatosis (HH) is recognized as a reference test to confirm the diagnosis of suspected HH or to predict its risk. The vast majority (typically >90%) of patients with clinically characterized HH are ho...

Apr 1st, 2011 - Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.|2011|Bacon BR,Adams PC,Kowdley KV,Powell LW,Tavill AS,|blood,diagnosis,physiopathology,therapy,metabolism,pathology,m...

May 18th, 2010 - Iron overload in humans is associated with a variety of genetic and acquired conditions. Of these, HFE hemochromatosis (HFE-HC) is by far the most frequent and most well-defined inherited cause when considering epidemiological aspects and risks fo...

May 10th, 2022 - This study will evaluate the long term performance and safety data for the Cadence™ Total Ankle System (CTAS) when used for primary arthroplasty in patients with primary arthritis (e.g. degenerative disease), secondary arthritis (e.g. post-traumat...

Apr 19th, 2022 - Hepatic steatosis may cause inflammation and fibrosis within the liver potentially leading to end-stage liver disease cirrhosis, liver failure and death. The condition is associated with several other chronic liver diseases like autoimmune hepatit...

Mar 2nd, 2022 - Oral iron supplementation is the treatment of choice in patients with iron deficiency anemia. In several developing countries, including India, iron is routinely supplemented to pregnant women, especially during the second and third trimesters of ...

Feb 24th, 2022 - Liver biopsy (LB) is essential for the diagnosis and evaluation of a variety of hepatic conditions, such as grading/staging of chronic liver disease secondary to alcohol, non-alcoholic steatohepatitis, viral hepatitis, hemochromatosis, Wilson's di...

Dec 6th, 2021 - The purpose of this study is to evaluate the efficacy and safety of deferasirox film coated tablet (FCT) versus phlebotomy for the management of iron overload in adults with HH at risk of iron-related morbidity. This evaluation will provide inform...

Oct 6th, 2021 - Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial, which found that for intermediate-risk women wit...

Apr 2nd, 2021 - Transcript:James M. Foran, MD, FRCPC: What is the role of the patient in deciding on iron chelation therapy? There are two oral chelating agents—a third one that’s approved in a different setting, deferiprone—and then there’s Desferal, or de...

Apr 2nd, 2021 - Transcript:David P. Steensma, MD: In patients with congenital anemias, like severe beta thalassemia, it’s clear that iron is a major contributor to morbidity and mortality. If you don’t adequately chelate patients with severe transfusion-defendant...

Apr 2nd, 2021 - Transcript: Ghassan K. Abou-Alfa, MD: Hello, and welcome to this OncLive® Peer Exchange® panel discussion titled Global Perspective on Treatment of Hepatocellular Carcinoma. The treatment of advanced hepatocellular carcinoma is complicated by ...

Apr 2nd, 2021 - Minsig Choi, MD: What are the etiology risk factors in the development of hepatocellular cancer? We all know that hepatocellular cancer or liver cancer is caused by a chronic irritation or inflammations. Usually the most common causes of this irri...